A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy

mAbs

Volumn 6, Issue 3, 2014, Pages 764-772

  Goh, Angeline X H ^a   Bertin Maghit, Sebastien ^a   Yeo, Siok Ping ^a   Ho, Adrian W S ^a   Derks, Heidi ^a   Mortellaro, Alessandra ^a   Wang, Cheng I ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Animal models; Antibody; Drug discovery; Immunotherapy; Interleukin 1

Indexed keywords

ALKALINE PHOSPHATASE; CANAKINUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; P 2D 7KK; P2D7KK; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; EPITOPE; INTERLEUKIN 1BETA; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHAGE DISPLAY; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; ARTHRITIS, EXPERIMENTAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; INFLAMMATION; MULTIPLE MYELOMA; NONOBESE DIABETIC MOUSE; PEPTIDE LIBRARY; PERITONITIS; PROTEIN ENGINEERING; RHESUS MONKEY; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ARTHRITIS, EXPERIMENTAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERLEUKIN-1BETA; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; PEPTIDE LIBRARY; PERITONITIS; PROTEIN ENGINEERING;

EID: 84899756347     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28614     Document Type: Article

References (41)

1. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, Jacobs M, Ryffel B, Quesniaux VF. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007; 179:1178-89; PMID:17617611
2. Graves DT, Chen CP, Douville C, Jiang Y. Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection. Infect Immun 2000; 68:4746-51; PMID:10899881; http://dx.doi.org/10.1128/IAI.68.8.4746-4751. 2000
3. Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, Fitzgerald KA. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009; 5:487-97; PMID:19454352; http://dx.doi.org/10.1016/j.chom.2009.05.002
4. Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006; 193:1419-26; PMID:16619190; http://dx.doi.org/10.1086/503363
5. Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, Mortellaro A. The rhapsody of NLRPs: master players of inflammation...and a lot more. Immunol Res 2012; 53:78-90; PMID:22427013; http://dx.doi.org/10.1007/s12026-012-8272-z
6. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011; 4:39-49; PMID:22096368; http://dx.doi.org/10.2147/JIR.S11330
7. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010; 11:897-904; PMID:20835230; http://dx.doi.org/10.1038/ni.1935
8. Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 2011; 8:135-45; PMID:21258359; http://dx.doi.org/10.1038/cmi.2010.81
9. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4:378-85; PMID:15251132; http://dx.doi.org/10.1016/j.coph.2004.03.010
10. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201:1355-9; PMID:15867089; http://dx.doi.org/10.1084/jem.20050640
11. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010; 21:157-63; PMID:20493414; http://dx.doi.org/10.1016/j.ejim.2010.03.005
12. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, Bohmann DJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010; 285:20607-14; PMID:20410301; http://dx.doi.org/10.1074/jbc.M110.115790
13. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9:47-52; PMID:12483208; http://dx.doi.org/10.1038/nm811
14. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, et al.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26-35; PMID:18163497; http://dx.doi.org/10.1002/art.23176
15. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin North Am 2005; 52:413-42, vi; PMID:15820374; http://dx.doi.org/10.1016/j.pcl.2005.01. 007
16. Solau-Gervais E, Robin C, Gambert C, Troller S, Danner S, Gombert B, Debiais F, Hankard R. Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine 2010; 77:47-9; PMID:20034832; http://dx.doi.org/10.1016/j.jbspin.2009.11.002
17. CDC National Diabetes Fact Sheet. General information and national estimates on diabetes in the US. 2007; 2008
18. Moreland NJ, Susanto P, Lim E, Tay MY, Rajamanonmani R, Hanson BJ, Vasudevan SG. Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries. Int J Mol Sci 2012; 13:2618-35; PMID:22489114; http://dx.doi.org/10. 3390/ijms13032618
19. Graves BJ, Hatada MH, Hendrickson WA, Miller JK, Madison VS, Satow Y. Structure of interleukin 1 alpha at 2.7-A resolution. Biochemistry 1990; 29:2679-84; PMID:2346741; http://dx.doi.org/10.1021/bi00463a009
20. Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A 2004; 101:12467-72; PMID:15306681; http://dx.doi.org/10. 1073/pnas.0401786101
21. Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991; 217:133-51; PMID:1988675; http://dx.doi.org/10.1016/0022-2836(91)90617-F
22. Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 2013; 425:94-111; PMID:23041424; http://dx.doi.org/10.1016/j.jmb.2012.09.021
23. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28; PMID:17352828; http://dx.doi.org/10.1186/ar2143
24. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999; 13:1117-25; PMID:10626139; http://dx.doi.org/10.1016/S0889-8588(05)70115-5
25. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Lust JA. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006; 26:83-95; PMID:16487028; http://dx.doi.org/10.1089/jir.2006.26.83
26. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84:114-22; PMID:19181644; http://dx.doi.org/10. 4065/84.2.114
27. Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene 1996; 169:147-55; PMID:8647439; http://dx.doi.org/10.1016/ 0378-1119(95)00821-7
28. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263:551-67; PMID:8918938; http://dx.doi.org/10.1006/jmbi.1996.0598
29. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
30. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293:865-81; PMID:10543973; http://dx.doi.org/10.1006/jmbi.1999.3192
31. Novotny J, Bruccoleri RE, Saul FA. On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. Biochemistry 1989; 28:4735-49; PMID:2475171; http://dx.doi.org/10.1021/bi00437a034
32. Kuroda D, Shirai H, Jacobson MP, Nakamura H. Computer-aided antibody design. Protein Eng Des Sel 2012; 25:507-21; PMID:22661385; http://dx.doi.org/ 10.1093/protein/gzs024
33. Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 2000; 1:253-63; PMID:11469383; http://dx.doi.org/10.2174/ 1389201003378906
34. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400; PMID:22444631; http://dx.doi.org/10.1016/j.immuni.2012.01.018
35. Dinarello CA. Targeting the pathogenic role of interleukin 1beta in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 2009; 84:105-7; PMID:19181642; http://dx.doi.org/10.4065/84.2.105
36. Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13:R54; PMID:21600050; http://dx.doi.org/10.1186/bcr2888
37. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; PMID:16785532
38. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; http://dx.doi.org/10.4049/jimmunol.1000303
39. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
40. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30:E9; PMID:11788735; http://dx.doi.org/10.1093/nar/30.2.e9
41. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007; 2:1269-75; PMID:17546023; http://dx.doi.org/10.1038/nprot.2007.173